| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2017 | SNY Sanofi | Sanofi | 10% Owner | Buy | 350,000 | $35.50 | $12,425,000.00 | +9.5% | |
| Aug 11, 2017 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | Buy | 10,000 | $1.55 | $15,500.00 | +16.1% | |
| Aug 10, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Umscheid Marc | Chief Strategy/ Mkt Officer | Buy | 600 | $5.31 | $3,186.00 | +21.5% | |
| Aug 10, 2017 | RMTI Rockwell Medical, Inc. | Richmond David S. | 10% Owner, See Footnote 1 | Buy | 605 | $6.34 | $3,836.18 | +0.3% | |
| Aug 10, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Miller Robert E | Chief Financial Officer | Buy | 2,264 | $5.30 | $11,999.20 | +26.7% | |
| Aug 10, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Schutz James J | Chief Executive Officer | Buy | 929 | $5.46 | $5,069.46 | +6.5% | |
| Aug 9, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Braunstein Douglas L | Director | Buy | 20,400 | $49.07 | $1,001,086.55 | +0.7% | |
| Aug 9, 2017 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 5,000 | $55.00 | $275,000.00 | -27.5% | |
| Aug 9, 2017 | PBH Prestige Consumer Healthcare Inc. | Boyko Jean A | SVP, Science And Technology | Sell | 12,876 | $52.12 | $671,097.12 | -48.5% | |
| Aug 9, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 15,354 | $55.00 | $844,470.00 | -12.5% | |
| Aug 8, 2017 | PCRX Pacira Biosciences, Inc. | Froimson Mark72 | Director | Buy | 100 | $37.13 | $3,713.16 | New | |
| Aug 4, 2017 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 22,500 | $50.00 | $1,125,000.00 | -8.0% | |
| Aug 1, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $54.91 | $82,365.00 | -15.8% | |
| Jul 31, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 220,000 | $83.09 | $18,279,477.84 | - | |
| Jul 27, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 8,734 | $50.00 | $436,700.00 | -15.1% | |
| Jul 27, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 25,000 | $36.50 | $912,500.00 | -1.5% | |
| Jul 27, 2017 | ANIK Anika Therapeutics, Inc. | Sherwood Charles H | CEO And Director | Sell | 63,799 | $50.79 | $3,240,351.21 | -26.7% | |
| Jul 24, 2017 | JNJ Johnson & Johnson | Stoffels Paulus | Exec VP, Chief Scientific Off | Sell | 102,692 | $133.14 | $13,672,628.53 | -44.6% | |
| Jul 20, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 25,000 | $35.50 | $887,500.00 | -1.5% | |
| Jul 20, 2017 | JNJ Johnson & Johnson | Caruso Dominic J | Exec VP, Finance; CFO | Sell | 82,591 | $136.72 | $11,291,478.12 | -36.4% | |
| Jul 17, 2017 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 10,000 | $3.05 | $30,526.00 | -0.9% | |
| Jul 12, 2017 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 10,000 | $18.05 | $180,500.00 | -1.7% | |
| Jul 12, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 3,735 | $44.90 | $167,701.50 | -15.0% | |
| Jul 6, 2017 | CANN Trees Corp (colorado) | Feinsod Michael | Director, 10% Owner | Sell | 50,000 | $1.00 | $50,000.00 | -4.5% | |
| Jul 6, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 32,000 | $36.49 | $1,167,680.00 | -44.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.